Skip to content

    Dabur India

    DABUR
    Fast Moving Consumer Goods·13 May 2025
    Management Summary

    Dabur India reported a challenging Q4 FY25 with consolidated revenue growing 0.6% in INR terms, primarily due to a 3.4% decline in India business, while international business grew strongly at 19.3% in constant currency. Full year FY25 revenue stood at INR 12,563 crores with PAT of INR 1,768 crores. The company outlined a refreshed Vision strategy targeting double-digit CAGR by FY28, focusing on premiumization, portfolio rationalization, and aggressive M&A, expecting sequential recovery in demand.

    Highlights

    13
    • Consolidated revenue for FY25 was INR 12,563 crores and PAT was INR 1,768 crores.

    • International business grew 19.3% in constant currency terms in Q4 FY25.

    • Market shares gained across 90% of the portfolio.

    • Emerging channels (modern trade, e-commerce, quick commerce) grew in double digits.

    • HPC Skincare grew 8%, driven by Gulabari franchise.

    • Home Care grew in low single digits, with Odonil gaining 67 basis points market share.

    • Hair Oils grew ahead of the category, gaining 196 basis points market share, and Coconut Hair Oil grew 11%.

    • Chyawanprash and Honey gained market shares of 162 bps and 75 bps respectively.

    • Glucose recorded a strong growth of 10% with market share gains of 112 basis points.

    • Hajmola franchise recorded 3.3% growth with market share gains of 233 basis points.

    • Dabur Health Juices grew 25% year-on-year.

    • Culinary business recorded a strong double-digit growth of 14% led by the Hommade brand.

    • Real Activ and coconut water recorded a robust growth of 11%, gaining 261 basis points market share in the J&N category.

    Concerns

    5
    • Consolidated revenue growth was 3.6% in constant currency terms for FY25, impacted by one-time inventory correction in India business in Q2.

    • Q4 FY25 consolidated revenue grew only 0.6% in INR terms (2.1% in constant currency).

    • India business declined by around 3.4% in Q4 FY25.

    • Standalone gross margin contracted by 240 basis points in Q4 FY25 due to inflation and competitive intensity.

    • Beverage portfolio was impacted by slowdown in urban consumption, leading to a decline in the overall portfolio.

    What Changed2

    vs Q1 FY26

    Guidance items9 → 7 (-2)Risks discussed4 → 6 (+2)

    Key financials

    Single quarter

    06 metrics
    1. 01Consolidated Revenue FY25₹12,563 Cr
    2. 02PAT FY25₹1,768 Cr
    3. 03Consolidated Revenue Growth Q4 FY25 (INR)60%+0.6%YoY
    4. 04Consolidated Revenue Growth Q4 FY25 (Constant Currency)2.1%+2.1%YoY
    5. 05Standalone Gross Margin Contraction Q4 FY25240 bps

    Segment breakdown

    International Business
    19.3% Growth Q4 FY25 (Constant Currency)
    India Business
    -3.4% Growth Q4 FY25
    HPC Skincare
    8% Growth Q4 FY25
    Home Care
    low single digits % Growth Q4 FY25
    Coconut Hair Oil
    11% Growth Q4 FY25
    Glucose
    10% Growth Q4 FY25
    Hajmola Franchise
    3.3% Growth Q4 FY25
    Dabur Health Juices
    25% Growth Q4 FY25
    Culinary Business
    14% Growth Q4 FY25
    Badshah
    6% Growth Q4 FY2512% Growth FY25
    Real Activ and Coconut Water
    11% Growth Q4 FY25
    List

    Guidance & targets

    5
    CategoryTargetPriority
    Revenue
    Full Year Value Growth
    high single digit, if not double-digit or near double-digit
    Medium
    Beverages
    Beverage Portfolio Growth
    low to mid-single digit
    Medium
    Beverages
    Beverage Business CAGR
    10% plus
    Medium
    Health Care
    Health Care CAGR
    7% to 8%
    High
    Odomos
    Odomos CAGR
    8% to 10%
    Medium

    India Business Growth

    Next quarter (Q1 FY26)
    CurrentDeclined ~3.4% in Q4 FY25
    TargetSequential improvement towards high single digit to double digit value growth

    Why it matters

    India business is the core market, and its recovery is crucial for overall company growth targets.

    So, I think sequential recovery is what we are also seeing. And we should also end the year with high single digit, if not double-digit or near double-digit kind of growth for the full year.

    How to verify

    key_financials.segment_breakdown[name='India Business'].metrics[label='Growth']

    Risks & concerns

    6
    RiskSeverity

    Slowdown in urban consumption, high food inflation, unfavorable season

    Challenging year due to these macro factors impacting business fundamentals.Management acknowledged

    medium

    General trade in urban markets under pressure

    Urban general trade remained weak, impacting overall India business.Management acknowledged

    medium

    Impact of delayed and contracted winters

    Affected sales of Honey and Chyawanprash, but company is launching all-season campaigns.Management acknowledged

    low

    Competitive intensity in beverage portfolio

    Impacted beverage business, especially in urban areas, leading to a decline in the overall portfolio.Management acknowledged

    medium

    Standalone gross margin contraction

    240 bps contraction in Q4 FY25 due to 4.5-5% inflation and inability to pass on full price increases.Management acknowledged

    medium

    Recycled plastic compliance challenges

    New regulations (10% for flexible, 30% for hard) are challenging due to limited capacity, higher cost of recycled plastic, and reluctance to use in food/Ayurvedic products; company has represented to the government.Both acknowledged

    medium

    Q&A highlights

    8

    “And the ones which stand out is that we shall weed and feed our portfolio and portfolio rationalization will happen and a clear exit path for some of the categories, which are the non-performers, have been identified to release capital, which is what I mentioned. So the categories that we will get out from is the tea category, and our baby diaper category, the sanitizing category, which actually happened and the Vita category.”

    Management detailed specific categories to be exited (tea, baby diapers, sanitizing, Vita) as part of the portfolio rationalization strategy.

    asked by Abneesh from Nuvama

    3 min read7 chapters

    Detailed Narrative

    01

    Q4 FY25 Performance Overview and Full Year Results

    Dabur India reported a challenging Q4 FY25, with consolidated revenue growing 0.6% in INR terms and 2.1% in constant currency. This was primarily due to a decline of approximately 3.4% in the India business. In contrast, the international business demonstrated strong performance, growing 19.3% in constant currency. For the full fiscal year 2025, the company achieved a consolidated revenue of INR 12,563 crores and a Profit After Tax (PAT) of INR 1,768 crores, reflecting a 3.6% constant currency growth for the year, impacted by a Q2 inventory correction.

    02

    Strategic Vision and Portfolio Refresh for FY28

    The company has unveiled a refreshed Vision strategy, aiming to achieve a sustainable double-digit CAGR in both top line and bottom line by financial year 2028. This strategy is built on seven key pillars, including continued investment in core brands like Dabur Red, Real, and Chyawanprash. A significant focus will be on premiumization and contemporization across the portfolio, with specific examples in hair care (serums, conditioners), oral care (benefit-led toothpaste), and healthcare (gummies, effervescents). Dabur also plans to rationalize underperforming products such as tea, baby diapers, and Vita to free up capital for bigger bets.

    03

    Category-wise Performance Highlights

    Within the HPC segment, Skincare recorded an 8% growth driven by the Gulabari franchise, while Home Care grew in low single digits, with Odonil gaining 67 basis points market share. Hair Oils grew ahead of the category, securing 196 basis points market share, and Coconut Hair Oil saw an 11% growth. The Healthcare portfolio experienced muted performance, as Honey and Chyawanprash were affected by delayed winters, though both gained market shares of 162 bps and 75 bps respectively. Glucose was a strong performer, growing 10% with 112 basis points market share gains.

    04

    Foods and Beverages Segment Performance

    The Foods business continued its growth momentum, with the Culinary segment growing 14% led by the Hommade brand. Badshah grew 6% in Q4 and 12% for the full FY25. The beverage portfolio faced challenges due to a slowdown in urban consumption, where 70% of its sales are concentrated. However, premium segments like Real Activ and coconut water recorded a robust 11% growth, contributing to a 261 basis points market share gain in the Juices & Nectars (J&N) category.

    05

    Gross Margin Pressure and Outlook

    Dabur experienced a standalone gross margin contraction of 240 basis points in Q4 FY25. This was primarily attributed to high inflation, which was around 4.5-5% in the quarter, and competitive intensity that limited the company's ability to pass on full price increases. While price increases of approximately 3.5% were implemented across categories (4.5-5% in Health Care, 1.5% in Personal Care, 1.6% in Beverages), the full impact was not realized. Management expects these price increases to flow through in Q1 FY26, which should aid in margin recovery.

    06

    Market Dynamics and Go-to-Market (GTM) Strategy

    Rural tertiary sales showed strong growth of 13-14% in Q4 FY25, according to Nielsen data, while urban markets remained flat. The company completed an inventory correction in the previous year, reducing distributor inventory from 30 to 21 days, which impacted primary sales but ensured healthy secondary sales. The refreshed GTM strategy includes stockist consolidation in urban India, expanding distribution in Class 3 and 4 towns and rural areas, and focusing on affordable INR10/20 bundle packs to leverage its rural infrastructure.

    07

    Recycled Plastic Regulation Challenges

    Dabur is currently recycling over 100% of the plastic it consumes. However, new government regulations requiring specific percentages of recycled material in packaging (10% for flexible, 30% for hard from April 1, 2025) pose challenges. The company, along with the industry, has represented to the government, citing limited capacity for recycled plastic, its higher cost compared to virgin plastic, and reluctance to use it in food, Ayurvedic, and pharmaceutical products due to health and safety concerns. The company seeks more time for the industry to develop capacity and reduce costs.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.